GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Completed · Phase 1

Conditions studied: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia

In brief

This phase I trial is studying the side effects and best dose of GTI-2040 and high-dose cytarabine in treating patients with refractory or relapsed acute myeloid leukemia. GTI-2040 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy, such as cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Giving GTI-2040 together with cytarabine may kill more cancer cells.

Key facts

Study ID

NCT00070551

Run by

National Cancer Institute (NCI)

People needed

51

Starts

2003-09-01

Last updated by the study team

2013-06-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed acute myeloid leukemia according to the WHO classification
• Relapsed or refractory disease, meeting 1 of the following criteria:
• Unresponsive to initial treatment
• Recurrent disease after treatment with prior conventional or high-dose chemotherapy with or without stem cell support
• CNS involvement allowed provided there are no residual leukemic cells detected in the cerebrospinal fluid after intrathecal or radiation chemotherapy
• Performance status - ECOG 0-2
• At least 4 weeks
• Bilirubin no greater than 2 times upper limit of normal* (ULN) (unless due to Gilbert's syndrome)
• AST and ALT no greater than 3 times ULN*
• Creatinine no greater than 1.5 mg/dL*
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Resting ejection fraction at least 50%*
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No prior allergy to study medications
• No ongoing or active infection requiring IV antibiotics
• No other concurrent uncontrolled illness
• No serious medical or psychiatric illness that would preclude giving informed consent
• More than 4 weeks since prior chemotherapy (except hydroxyurea) (6 weeks for nitrosoureas or mitomycin)
• No other concurrent chemotherapy
• No concurrent hormonal therapy except steroids for adrenal failure and hormones for non-disease-related conditions (e.g., insulin for diabetes)
• More than 4 weeks since prior radiotherapy

Where it is running

• Ohio State University Medical Center — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.